Enhertu: NICE Approval Expands NHS Breast Cancer Care
AstraZeneca and Daiichi Sankyo's Enhertu received NICE approval for HER2-positive breast cancer treatment. The drug, priced at £1,455 per 100mg vial, was initially rejected due to cost but gained approval after NICE's valuation methodology change. It extends patient lifespans by an average of seven months.
How this was made
The 30-second read
Why it matters
NICE recommendation removes a key barrier, opening the UK market and potentially influencing other European HTA bodies.
Market read
Regulatory approval could drive short‑term upside for AstraZeneca and Daiichi Sankyo while signaling broader acceptance of ADC therapies.
What to watch
Potential pricing negotiations with NHS may delay revenue realization.
Background
Enhertu, an antibody‑drug conjugate for HER2‑low breast cancer, previously received FDA approval but faced UK cost‑effectiveness hurdles.
Ticker impact
NICE and CHMP recommendation expands NHS use of Enhertu, a drug co‑developed by AstraZeneca.
potential upside as market prices in expanded NHS reimbursement.
Approval removes a major market barrier and signals future revenue growth.
Market effects
Strengthens the oncology ADC segment and may boost peer valuations.
UK healthcare market sees new high‑cost therapy option, potentially raising NHS oncology spend.
Highlights regulatory pathways for high‑price cancer drugs in major economies.
Counterpoint
High manufacturing cost could limit uptake despite approval, pressuring margins.
Key entities
- DrugEnhertu
Antibody‑drug conjugate for HER2‑low metastatic breast cancer.
- RegulatorNICE
UK health technology assessment agency that approved the drug.
